Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats

Japanese Journal of Pharmacology

Volumn 75, Issue 3, 1997, Pages 275-281

  Egawa, Takashi ^a,b   Mishima, Kenichi ^a   Matsumoto, Yoshiaki ^a   Iwasaki, Kiyo ^a   Iwasaki, Katsunori ^a   Fujiwara, Michihiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b Yame General Hospital   (Japan)

Author keywords

Passive avoidance; Radial arm maze; Rolipram; Scopolamine; Tremor

Indexed keywords

CYCLIC AMP; OXOTREMORINE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; SCOPOLAMINE;

AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CHOLINERGIC SYSTEM; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; ENZYME INHIBITION; INTRAPERITONEAL DRUG ADMINISTRATION; ISOMER; LEARNING DISORDER; MALE; MAZE TEST; MOUSE; NONHUMAN; NORADRENERGIC SYSTEM; ORAL DRUG ADMINISTRATION; PASSIVE AVOIDANCE; RAT; TREMOR;

EID: 0031451614     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.75.275     Document Type: Article

References (36)

1. Richter JA, Perry EK and Tomlinson BE: Acetylcholine and choline levels in post-mortem human brain tissue: preliminary observations in Alzheimer's disease. Life Sci 26, 1683-1689 (1980)
2. Perry EK: The cholinergic system in old age and Alzheimer's disease. Age Aging 9, 1-8 (1980)
3. Gauthier S, Masson H, Gauthier L, Bouchard R, Collier B, Bacher Y, Bailey R, Becker R, Bergman H, Charrbonneau R, Dastoor D, Gayton D, Kenney J, Kissel C, Krieger M, Kushnir S, Lamontagne A, St-Martin M, Morin J, Nair NPV, Neirinck L, Ratner J, Suissa S, Tesfaye Y and Vida S: Tetrahydroaminoacridine and lecithin in Alzheimer's disease. In Current Research in Alzheimer Therapy, Edited by Giacobini E and Becker R, pp 237-245, Taylor and Francis, New York (1988)
4. Kumar V: Efficacy and side effects of THA in Alzheimer's disease patients. In Current Research in Alzheimer Therapy, Edited by Giacobini E and Becker R, pp 225-229, Taylor and Francis, New York (1988)
5. Nyback H, Nyman H, Ohman G, Nordgren I and Lindstrom B: Preliminary experiences and results with THA for the amelioration of symptoms research in Alzheimer's disease. In Current Research in Alzheimer Therapy, Edited by Giacobini E and Becker R, pp 231-236, Taylor and Francis, New York (1988)
6. Summers WK, Majovski LV, Marsh GM, Tachiki K and Kling A: Oral tetrahydroaminoacridine in long term treatment of senile dementia, Alzheimer type. N Engl J Med 315, 1241-1245 (1986)
7. Fitteen J, Perryman K and Gross P: THA-memory and cognitive enhancement in mouse, monkey and man. In Current Research in Alzheimer Therapy, Edited by Giacobini E and Becker R, pp 211-216, Taylor and Francis, New York (1988)
8. Sherman KA and Messamore E: Cholinesterase inhibitor therapy for Alzheimer dementia: What do animal models tell us? Alzheimer Dis Assoc 2, 216 (1988)
9. Flood JF, Smith GE and Cherkin A: Memory enhancement: supra-additive effect of subcutaneous cholinergic drug combinations in mice. Psychopharmacology (Berlin) 86, 61-67 (1985)
10. Toumane A, Durkin T, Marighetto A, Galey D and Jaffard R: Differential hippocampal and cortical cholinergic activation during the acquisition, retention, reversal and extinction of a spatial discrimination in an 8-arms radial maze by mice. Behav Brain Res 30, 225-234 (1988)
11. Yin JC, Del Vecchio M, Zhou H and Tully T: CREB as a memory modulator: induced expression of a dCREB2 activator isoform enhances long-term memory in Drosophila. Cell 81, 107-115 (1995)
12. Decker MW and Gallagher M: Scopolamine-disruption of radial arm maze performance: Modification by noradrenergic depletion. Brain Res 417, 59-69 (1987)
13. Decker MW and McGaugh JL: The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 7, 151-168 (1991)
14. Luine V, Bowling D and Hearns M: Spatial memory deficits in aged rats: Contribution of monoaminergic systems. Brain Res 537, 271-278 (1990)
15. Brandeis R, Sapir M, Kapon Y, Borelli G, Cadel S and Valsecchi B: Improvement of cognitive function by MAO-B inhibitor L-deprenyl in aged rats. Pharmacol Biochem Behav 39, 297-304 (1991)
16. Knoll J: The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: a personal view. Pharmacol Toxicol 70, 317-321 (1992)
17. Wachtel H: Dysbalance of neuronal second messenger function in the etiology of affective disorders: a pathophysiological concept hypothesizing defects beyond first messenger receptors. J Neural Transm 75, 21-29 (1989)
18. Nehling A, Daval JL and Debry G: Caffeine and the central nervous system: Mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Rev 17, 139-170 (1992)
19. Beavo JA: Multiple isozymes of cyclic nucleotide phosphodiesterase. Adv Second Messenger Phosphoprotein Res 22, 1-38 (1988)
20. Bertolino A, Crippa D, DiDio S, Fichte K, Musmeci G, Porro V, Rapisarda V, Sastre-Hernandez M and Schratzer M: Rolipram versus imipramine in inpatients with major, "minor" or atypical depressive disorder: a double-blind double-dummy study aimed at testing a novel therapeutic approach. Int Clin Psychopharmacol 3, 245-253 (1988)
21. Bobon D, Breulet M, Gerard-Vandenhove M-A, Guiot-Goffioul F, Plomteux G, Sastre-y-Hernandez M, Schratzer M, Troisfontaine B, von Frenkell R and Wachtel H: Is phosphodiesterase inhibition a new mechanism of antidepressant action? Eur Arch Psychiatry Neurol 238, 2-6 (1988)
22. Eckmann F, Fichte K, Meya U and Sastre-y-Hernandez M: Rolipram in major depression: results of a double-blind comparative study with amitriptyline. Curr Ther Res 43, 291-295 (1988)
23. Schoffelmeer ANM, Wardeh G and Mulder AH: Cyclic AMP facilitates the electrically evoked release of radiorabelled noradrenaline, dopamine and 5-hydroxytryptamine from rat brain slices. Naunyn Schmiedebergs Arch Pharmacol 330, 74-76 (1985)
24. Wachtel H: Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology 22, 267-272 (1983)
25. Olton DS and Samuelson RJ: Remembrance of places past: Spatial memory in rats. J Exp Psychol Anim Behav Process 2, 97-116 (1976)
26. Fujiwara M: Effect of Kampo medicine preparations using the pathological model of dementia. In Brain Research Conference for Japanese Kampo Medicine 1990, Edited by Hagino N, Yoshida M and Hasegawa K, pp 67-81, Medical Journal-sha Co, Ltd, Tokyo (1991)
27. Iwasaki K, Matsumoto Y and Fujiwara M: Effect of nebracetam on the disruption of spatial cognition in rats. Jpn J Pharmacol 58, 117-126 (1992)
28. Fujiwara M, Iwasaki K and Matsumoto Y: Involvement of brain noradrenaline in spatial cognition in rats. Jpn J Pharmacol 46, Suppl 18P (1988)
29. Schneider HH, Yamaguchi M, Andrews JS and Stephens N: Discriminative stimulus properties of the stereoisomers of the phosphodiesterase inhibitor rolipram. Pharmacol Biochem Behav 50, 211-217 (1995)
30. Schneider HH: Brain cAMP response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation. Biochem Pharmacol 33, 1690-1693 (1984)
31. Tanaka Y, Sakurai M, Goto M and Hayashi S: Effects of xanthine derivatives on hippocampal long-term potentiation. Brain Res 522, 63-68 (1990)
32. Morimoto BH and Koshland DE Jr: Identification of cyclic AMP as the response regulator for neurosecretory potentiation: A memory model system. Proc Natl Acad Sci USA 88, 10835-10839 (1991)
33. Morris RGM, Anderson E, Lynch GS and Baudry M: Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP-5. Nature 319, 774-776 (1986)
34. Fu WM: Potentiation of acetylcholine responses in Xenopus embryonic muscle cells by dibutyryl cAMP. Pflugers Arch 425, 439-445 (1993)
35. Nakamura M, Nishio C, Nonomura T and Hatanaka H: High potassium and cyclic AMP analog promote neuronal survival of basal forebrain cholinergic neurons in culture from postnatal 2-week-old rats. Brain Res Dev Brain Res 81, 218-229 (1994)
36. Horowski R and Sastre-y-Hernandez M: Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr Ther Res 38, 23-29 (1985)